Climb Bio reports 70% Gd-IgA1 reduction with CLYM116 in Phase 1 trials
CLYM•Climb Bio reported a 70% reduction in Gd-IgA1 with CLYM116 in Phase 1 trials. Healthy volunteer studies also showed sustained APRIL suppression, and the drug was generally well tolerated.
1. Phase 1 results
Climb Bio and Mabworks presented Phase 1 results for CLYM116/MIL116, an IgA nephropathy candidate, at ASN Kidney Week 2026. Healthy volunteer studies showed sustained APRIL suppression and reductions in disease-related biomarkers, supporting dosing every 12 weeks; no dose-limiting toxicities or treatment-related serious adverse events were reported.
2. Trial plans
The NAVIGATE-2 Phase 2 trial is enrolling patients, with initial data expected in the first half of 2027. A global Phase 3 trial is expected to begin in 2027, pending regulatory feedback.
